Clinical utility of exemestane in the treatment of breast cancer

about

Improving Adjuvant Hormone Therapy Use in Medicaid Managed Care-Insured Women, New York State, 2012-2014.The therapeutic potential of mTOR inhibitors in breast cancer.

P2860

Q37226830-6AC1783A-3757-41E1-AB58-5D6B3B4EF4C9 Q38802412-FD9E5A05-55A2-4214-9A0B-248CA9F6C706

P2860

Clinical utility of exemestane in the treatment of breast cancer

Item

http://www.wikidata.org/entity/Q35683807

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical utility of exemestane in the treatment of breast cancer

@ast

Clinical utility of exemestane in the treatment of breast cancer

@en

type

Item

label

Clinical utility of exemestane in the treatment of breast cancer

@ast

Clinical utility of exemestane in the treatment of breast cancer

@en

prefLabel

Clinical utility of exemestane in the treatment of breast cancer

@ast

Clinical utility of exemestane in the treatment of breast cancer

@en

P1476

Clinical utility of exemestane in the treatment of breast cancer

@en

P2093

Andrea Milani

http://www.w3.org/2001/XMLSchema#string

Caterina Aversa

http://www.w3.org/2001/XMLSchema#string

Giorgia Zucchini

http://www.w3.org/2001/XMLSchema#string

Rossella Martinello

http://www.w3.org/2001/XMLSchema#string

P2860

Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer.

P304

551-563

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/IJWH.S69475

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Filippo Montemurro

Elena Geuna

P577

2015-05-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26064072

http://www.w3.org/2001/XMLSchema#string

P932

4455847

http://www.w3.org/2001/XMLSchema#string

Clinical utility of exemestane in the treatment of breast cancer

about

P2860

P2860

Clinical utility of exemestane in the treatment of breast cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P932